Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Rheumatology International|February 27, 2025
Increased retinal thickness in sarcoidosis patients with ocular system involvement visualized with optical coherence tomography: a cross-sectional studyKeld-Erik Byg, Torkell Ellingsen, Jimmi Wied, et al.Infectious Diseases (London, England)|February 15, 2021
Serum levels of neurofilament light chain, neuron-specific enolase and S100 calcium-binding protein B during acute bacterial meningitis: a prospective cohort studyMads Hjortdal Grønhøj, Tobias Sejbaek, Rasmus Würgler Hansen, et al.Journal of Neuroimmunology|July 2, 2023
Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trialMaria L Elkjaer, Rikke M Lohse, Mark Burton, et al.Journal of the Neurological Sciences|January 26, 2024
High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosisSimone Hjæresen, Eirikur Benedikz, Tobias Sejbaek, et al.Journal of Neuroimmunology|June 19, 2022
A prospective, one-year follow-up study of patients newly diagnosed with neurosarcoidosisKeld-Erik Byg, Zsolt Illes, Tobias Sejbaek, et al.Journal of Neurology, Neurosurgery, and Psychiatry|October 16, 2019
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patientsTobias Sejbaek, Helle Hvilsted Nielsen, Natasha Penner, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2026
Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic EncephalopathyElise Jonasson, Lea L Grønkjær, Birgitte G Jacobsen, et al.Brain Sciences|March 6, 2021
Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in NeurosarcoidosisKeld-Erik Byg, Helle H Nielsen, Tobias Sejbaek, et al.Therapeutic Advances in Neurological Disorders|September 19, 2025
Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlookLuisa Klotz, Thomas Berger, Wallace J Brownlee, et al.Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2017
An observational study of alemtuzumab following fingolimod for multiple sclerosisMark Willis, Owen Pearson, Zsolt Illes, et al.Pageof 4